Patient’s sex/age (years) | Cytology positive | Cytology suspicious | ASO positive | ARMS positive* |
---|---|---|---|---|
*Based on a final diagnosis of malignancy, which was established by histological and/or clinical findings (symptomatology, imaging studies, and course of the disease). | ||||
ARMS, amplification refractory mutation system; ASO, allele specific oligonucleotide; PCR, polymerase chain reaction. | ||||
Female/31 | – | – | 12 Asp | – |
Male/60 | – | – | 12 Asp | – |
Male/43 | – | – | Ala | Ala (9%) |
Male/46 | – | + | – | – |
Female/85 | – | – | Cys | – |
Female/44 | – | + | – | – |
Female/54 | – | – | – | Cys (1.25%) |
Male/72 | – | + | – | – |
Male/41 | – | – | 12 Asp | – |
Male/38 | – | – | Ala | Ala (12.5%) |
Male/44 | – | + | – | – |
Female/60 | – | – | 12 Asp | 12 Asp (0.95%) |
Male/55 | + | – | Val | – |
Male/51 | – | + | – | – |
Female/40 | + | – | 12 Asp | Val (0.24%) |